Since gaining independence in 1947, India’s chemical and pharmaceutical sectors have evolved into global leaders in generic drug manufacturing; however, the country has not fully realized its potential in original drug discovery. This paper examines the historical, economic, and institutional factors that shaped this trajectory. A key policy milestone, the Indian Patents Act of 1970, fostered the growth of a robust generics industry by recognizing only process patents, thereby improving access to affordable medicines but limiting incentives for innovation. Post independence economic constraints, including limited capital availability and competing national priorities, further restricted investment in high-risk, long-term drug discovery. Additionally, weak academia–industry linkages and inadequate translational research frameworks hindered the conversion of scientific knowledge into viable drug candidates. Infrastructure deficits, fragmented research ecosystems, and regulatory uncertainties compounded these challenges, while talent migration reduced the domestic concentration of advanced research expertise. Indian pharmaceutical firms strategically prioritized generics, active pharmaceutical ingredients, and contract research services, benefiting from lower risk and faster returns but delaying engagement in novel drug development. Although the introduction of product patents in 2005 marked a shift toward innovation, the transition has been gradual due to late entry, high attrition rates, and financial risks associated with drug discovery. Despite these limitations, India is now undergoing a transformation driven by expanding biotechnology initiatives, increased government support, and improved global integration. With its strong foundation in synthetic chemistry and cost-efficient research capabilities, India is well-positioned to evolve into an innovation-driven pharmaceutical hub. This analysis underscores that India’s historical focus on accessibility over innovation, while socially impactful, delayed its emergence in global drug discovery—a gap that is now beginning to narrow.

Historical context and policy foundations at independence in 1947, India inherited a limited industrial base and almost no indigenous pharmaceutical innovation capacity. The early decades were shaped by a national priority: self-reliance in essential medicines, rather than breakthrough drug discovery. The pivotal moment came with the Indian Patents Act of 1970, which recognized only process patents (not product patents) for pharmaceuticals. This allowed Indian companies to legally reverse engineer drugs developed elsewhere and manufacture them at low cost. Impact: Enabled growth of a strong generic drug (1,2) industry Improved domestic access to affordable medicines. Reduced incentives for original drug discovery, since innovators could not secure product exclusivity. Thus, policy deliberately prioritized public health access over innovation incentives.

Economic Constraints and Capital Limitations:

Drug discovery is a high risk, capital intensive, and long cycle process, often requiring: 10–15 years of research. Billions of dollars in investment. Advanced infrastructure and multidisciplinary expertise. 

Post independence India faced:

Limited capital markets competing developmental priorities (poverty alleviation, agriculture, infrastructure). Low private sector appetite for high-risk R&D. Indian pharmaceutical firms therefore focused on: Generics manufacturing. Process chemistry optimization. Export-driven growth after the 1990s (3,4). This model generated revenue but did not build strong pipelines in novel chemical entities (NCEs).

Weak Academia Industry Linkages (5,6)

A critical gap has been the disconnect between academic research and industrial application. Challenges included: Academic institutions focused on basic science, often without translational pathways. Limited technology transfer mechanisms. Lack of interdisciplinary collaboration between chemists, biologists, and clinicians. While India produced highly skilled chemists, their work rarely transitioned into: Drug candidates. Clinical pipelines. Commercial products.

Infrastructure and Ecosystem Deficits: Drug discovery requires a sophisticated ecosystem:

High throughput screening platforms. Advanced computational chemistry. Preclinical and clinical trial networks. Regulatory science expertise. Historically, India lagged in: Integrated drug discovery platforms. Early-stage venture funding. Specialized biotech infrastructure. Even when capabilities improved after economic liberalization (1991) (7,8), the ecosystem remained fragmented.

Regulatory and Policy Uncertainty (9,10)

Frequent policy shifts and regulatory delays affected innovation: Weak intellectual property. protection prior to 2005 discouraged multinational R&D investment. Transition to TRIPS compliant product patents (2005) created uncertainty for domestic firms. Regulatory processes for clinical trials were often perceived as slow or inconsistent. This environment made long-term R&D investments less predictable.

Talent Utilization and Brain Drain (11,12)

India has produced world-class scientists, particularly in chemistry and medicinal chemistry. However: Many migrated to research hubs in the US and Europe (“brain drain”). Domestic opportunities in cutting-edge drug discovery were limited. Industry roles emphasized process chemistry over discovery science. As a result, India contributed significantly to global pharma but often from outside its borders.

Industry Strategy: Generics Over Innovation (13,14)

Indian pharmaceutical companies such as large domestic firms built global leadership in: Generic drug manufacturing. Active pharmaceutical ingredients (APIs) Contract research and manufacturing services (CRAMS). This strategy was rational because it offered: Lower risk. Faster returns. Strong global demand. However, it led to: Underinvestment in first-in-class drug discovery. Limited experience in navigating full innovation pipelines

Late Start in Innovation Transition (15,16)

After 2005 (product patent regime), Indian firms began investing in drug discovery. However: They entered decades later than global competitors; High attrition rates in drug discovery discouraged sustained investment. Several companies scaled back discovery programs after costly failures. Thus, the transition from generics to innovation has been slow and uneven.

Cultural and Institutional Factors (17,18)

Innovation ecosystems require: Risk tolerance. Long-term vision. Collaboration across sectors

Historically, Indian industry and institutions: Preferred incremental improvements over disruptive innovation. Operated in silos. Faced bureaucratic constraints in research funding and approvals

Emerging Strengths and Future Outlook (19,20)

Despite past limitations, India is now showing signs of transformation: Growth in biotech startups and deep-tech ventures. Expansion of contract research organizations (CROs). Increasing government support for innovation (e.g., biotech missions). Improved global integration of Indian scientists. India’s strengths today include: Strong foundation in synthetic chemistry. Cost-efficient research capabilities. Large and diverse patient population for clinical studies

India’s limited success in original drug discovery since independence is not due to a lack of scientific capability, but rather the result of policy choices, economic constraints, and ecosystem gaps. The post-independence model successfully delivered affordable medicines to millions, positioning India as the “pharmacy of the developing world.” However, this came at the cost of delayed investment in innovative drug discovery. As the ecosystem matures with stronger IP regimes, better funding, and improved academia–industry collaboration India is now positioned to transition from a generics powerhouse to an innovation-driven pharmaceutical hub.